BGI’s attempt in November to acquire US human sequencing service Complete Genomics, an offer extended to December 14, is the latest facet of the Shenzhen-based genomics giant’s commercialization strategy. BGI, which has made a name for itself as a world-leading sequencing center, is now set to expand its commercial activities to the healthcare, agriculture and even aquaculture sectors. It is already making forays into the market for noninvasive cell-free fetal DNA monitoring, is positioning itself to offer turnkey genomic analysis to research and clinical markets, and is actively translating genome information into its marker-assisted crop breeding programs.
展开▼
